Austin, Texas 78745

  • Opioid Withdrawal

Purpose:

The objective of this study is to evaluate whether tAN via the tragus (vagal) and auriculotemporal (trigeminal) nerve pathways results in a clinically meaningful reduction in opioid withdrawal symptoms.


Study summary:

This study is designed as a pilot, single-center, non-randomized, uncontrolled, clinical trial in which subjects will be consented, receive a baseline assessment, and receive tAN treatment and assessment every day during their 3 to 5-day detox treatment. Use of opioid-based medication assisted therapy (MAT) will not be permitted at any point during the study. Use of non-opioid-based MATs (i.e. comfort or rescue medications) will not be permitted until after the subject has completed the 60 minute COWS assessment to ensure changes in COWS score at 60 minutes are only the result of tAN therapy.


Criteria:

Inclusion Criteria: - Current opioid dependence; prescriptive or non-prescriptive - COWS score is ≥ 13 or in the opinion of the investigator the subject is in moderate to severe withdrawal - 18-65 years of age - English proficiency - Participants must be able to provide informed consent and function at an intellectual level sufficient for study requirements Exclusion Criteria: - Current evidence of an uncontrolled and/or clinically significant medical condition - History of seizures or epilepsy - History of neurological diseases or traumatic brain injury - Participants using long-acting opioids such as methadone or buprenorphine for a period of five or more consecutive days prior to enrollment - Recent suicide attempt leading to current hospital admission or continued expressed suicidal ideation - Presence of devices (e.g., pacemakers, cochlear prosthesis, neurostimulators) - Abnormal ear anatomy or ear infection present - Women of childbearing potential not using adequate contraception as per investigator judgement or not willing to comply with contraception for the duration of the study - Females who are pregnant or lactating - Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant's ability to participate in the trial


NCT ID:

NCT04731935


Primary Contact:

Study Director
Navid Khodaparast, PhD
Spark Biomedical, Inc.

Carlos Tirado, MD, MPH
Phone: (512) 213-6710
Email: carlost@carmahealth.com


Backup Contact:

N/A


Location Contact:

Austin, Texas 78745
United States

Caroline Hedenberg, LCSW
Phone: (512) 213-6710
Email: carolineh@carmahealth.com

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: June 16, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.